Research programme: secreted protein therapeutics - ARCA biopharma/Kyowa Hakko Kirin

Drug Profile

Research programme: secreted protein therapeutics - ARCA biopharma/Kyowa Hakko Kirin

Alternative Names: Wnt therapeutics program

Latest Information Update: 08 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Brewery; Nuvelo
  • Developer ARCA biopharma Inc
  • Class Proteins
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Mucositis

Most Recent Events

  • 05 Oct 2012 Discontinued - Preclinical for Cancer in USA (IV)
  • 05 Oct 2012 Discontinued - Preclinical for Inflammatory bowel disease in USA (IV)
  • 05 Oct 2012 Discontinued - Preclinical for Mucositis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top